China In-Vitro Diagnostics (IVD) Market 2007-2017 & 2018-2024 with Company Analysis of Roche Diagnostics, Sysmex, Mindray Medical, Shanghai Kehua Bio & Abbott Laboratories
Jan 07, 2019, 17:00 ET
DUBLIN, Jan 7, 2019 /PRNewswire/ --
The "China In-Vitro Diagnostics (IVD) Market, By Diagnostics, and Companies" report has been added to ResearchAndMarkets.com's offering.
China In-Vitro Diagnostics (IVD) Market is projected to exceed US$ 12 Billion by the end of year 2024
China In-Vitro Diagnostics (IVD) Market is growing significantly and is expected to continue its ongoing trend during the forecast period as well, owing to rapidly increasing middle class population who is now willing to pay more for better healthcare services and aging population who are more vulnerable to contagious diseases. Also, Chinese aging population is experiencing an outburst of chronic diseases which includes cancer, diabetes and cardiovascular disease. All of these diseases can be diagnosed and monitored using IVD products.
In addition; some other factors which can be attributed to China IVD market include growing prevalence of chronic lifestyle and infectious diseases, public health awareness, transformation of medical models, increasing demand of tests from the rural areas and support from the Chinese government to provide better healthcare infrastructure throughout the nation.
Profiles of Companies Covered in the Report:
- Roche Diagnostics
- Sysmex Corporation
- Mindray Medical International Limited
- Shanghai Kehua Bio-Engineering Co. Ltd.
- Abbott Laboratories
Profiles of Private Clinical Labs and Diagnostic Services Companies in China
- Zhejiang Di'an Diagnostics Technology Co., Ltd
- ADICON Clinical Laboratories
- Guangzhou Kingmed Diagnostics Center Co. Ltd.
- Kindstar Global (Privately held)
- BGI-Shenzhen (Privately held)
- OriGene Technologies (Privately held)
Key Topics Covered:
1. Executive Summary
2. China IVD Market (2007 - 2024)
3. Market Share - China In Vitro Diagnostics (IVD) (2011 - 2024)
3.1 Segments - China IVD
3.2 Companies - China IVD
4. Segments - China IVD Market (2007 - 2024)
4.1 Clinical Chemistry Market
4.2 Immunoassay Market
4.3 Hematology Market
4.4 Coagulation Market
4.5 Microbiology Market
4.6 Molecular Diagnostic Market
4.7 Self Monitoring of Blood Glucose (SMBG) Market
4.8 Point of Care Testing (POCT) Market
5. Development Environment of Chinese IVD Industry
5.1 Healthcare Reforms
5.2 Improving Quality at Grass - Root Level
5.3 Embracing Technology
6. China: Health Insurance and Reimbursement Policies
6.1 Health Insurance System
6.1.1 Basic Medical Insurance
6.1.2 Insurance for Other Groups
6.1.3 Rural Medical Insurance
6.1.4 Private Health Insurance
6.2 Reimbursement Rules
6.2.1 Device Reimbursement
6.2.2 Reimbursement for In - Vitro Diagnostics (IVDs)
7. Registration of In Vitro Diagnostic Reagents in China
7.1 Registration and Filing
7.2 Filing Obligation for Clinical Trials
7.3 Clinical Trial Institutions
7.4 Elimination of IVD Loophole for Research
7.5 Change of Manufacturing Address
7.6 Change of Main Supplier of an Antigen or Antibody
7.7 Update on China In - Vitro Diagnostics Registration
7.7.1 IVD Product Registration in China
7.7.2 China IVD Type Testing Process
7.7.3 Clinical Trials for IVD Products in China
8. Medical Devices and Reagents Class Registration in China
8.1 Process of Medical Device Registration in China
8.2 Classification of In - vitro Diagnostic Reagents in China
8.2.1 Class III: Highest Risk
8.2.2 Class II: Medium Risk
8.2.3 Class I: Lower Risk
8.3 China In - Vitro Diagnostics Reagents
8.3.1 Blood Screening Reagents - Drug Administration
8.3.2 Varieties of Blood Screening Reagents
8.3.3 Blood Screening Reagent Test
8.3.4 Nucleic Acid Detection Kits for Blood Screening
8.3.5 Radioactive Reagents - Drug Administration
8.3.6 Diagnostic Reagents - Medical Devices Management
9. China IVD Industry Drivers
9.1 Increasing Demand from Middle Class for High Quality Healthcare Products
9.2 Rising Incidences of Lifestyle Diseases in China
9.3 Growth in Private Hospitals & Independent Diagnostic Centers
9.3.1 Increasing the Number of Hospital Beds across all Medical Institutions
10. China IVD Industry Challenges
10.1 Chinese Local Firms Lack of Expertise in Advanced Technology
10.2 Cost Factor Restricts the Contribution of Global IVD Companies in the Chinese IVD Market
10.3 Reimbursement Rates varies from Province to Province in China
10.3.1 Chinese Government Regulating Laboratory Testing in China
11. Company Sales Analysis (2011 - 2024)
11.1 Roche Diagnostics - China IVD Sales & Forecast
11.2 Sysmex Corporation - China IVD Sales & Forecast
11.3 Mindray Medical International Limited - China IVD Sales & Forecast
11.4 Shanghai Kehua Bio - Engineering Co. Ltd. - China IVD Sales & Forecast
11.5 Abbott Laboratories - China IVD Sales & Forecast
11.6 Others - China IVD Sales & Forecast
12. Profiles of Select Private Clinical Labs and Diagnostic Services Companies
12.1 Zhejiang Di'an Diagnostics Technology Co., Ltd.
12.1.1 Products and Services Offered by Di'an
12.2 ADICON Clinical Laboratories (Privately held)
12.2.1 Products and Services Offered by ADICON
12.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
12.3.1 Products and Services Offered by Kingmed
12.4 Kindstar Global (Privately held)
12.4.1 Products and Services Offered by Kindstar
12.5 BGI - Shenzhen
12.5.1 BGI's Innovative Approach
12.6 OriGene Technologies
12.6.1 Products and Services Offered by OriGene
For more information about this report visit https://www.researchandmarkets.com/research/7bdprw/china_invitro?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
